Financial reports
10-K
2023 FY
Annual report
16 Apr 24
NT 10-K
Notice of late annual filing
1 Apr 24
10-Q
2023 Q3
Quarterly report
20 Nov 23
NT 10-Q
Notice of late quarterly filing
15 Nov 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
10-Q
2023 Q1
Quarterly report
23 May 23
NT 10-Q
Notice of late quarterly filing
15 May 23
10-K
2022 FY
Annual report
9 Feb 23
NT 10-K
Notice of late annual filing
30 Jan 23
10-Q
2022 Q3
Quarterly report
12 Sep 22
Current reports
8-K/A
Financial Statements and Exhibits
19 Apr 24
8-K
Departure of Directors or Certain Officers
3 Apr 24
8-K
Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome
29 Mar 24
8-K
Entry into a Material Definitive Agreement
5 Mar 24
8-K
Departure of Directors or Certain Officers
23 Feb 24
8-K
Unregistered Sales of Equity Securities
9 Feb 24
8-K
Immunome To Acquire AL102, A Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals
6 Feb 24
8-K/A
Consolidated Financial Statements
3 Jan 24
8-K
Ayala Pharmaceuticals Announces Closing of Merger with Biosight
20 Oct 23
8-K
Entry into a Material Definitive Agreement
21 Sep 23
Registration and prospectus
S-8 POS
Registration of securities for employees (post-effective amendment)
15 Apr 24
S-8 POS
Registration of securities for employees (post-effective amendment)
15 Apr 24
S-8 POS
Registration of securities for employees (post-effective amendment)
15 Apr 24
S-8 POS
Registration of securities for employees (post-effective amendment)
15 Apr 24
S-8 POS
Registration of securities for employees (post-effective amendment)
15 Apr 24
S-8 POS
Registration of securities for employees (post-effective amendment)
15 Apr 24
S-8 POS
Registration of securities for employees (post-effective amendment)
15 Apr 24
S-8 POS
Registration of securities for employees (post-effective amendment)
15 Apr 24
S-8 POS
Registration of securities for employees (post-effective amendment)
15 Apr 24
D
$433.83 k in equity / securities to be acquired / Shares of common stock, sold $433.83 k, 3 investors
2 Nov 23
Proxies
DEFM14C
Information related to merger
5 Mar 24
PREM14C
Preliminary information related to merger
20 Feb 24
DEF 14A
Definitive proxy
23 Jun 23
DEF 14A
Definitive proxy
12 Dec 22
PRE 14A
Preliminary proxy
2 Dec 22
DEF 14A
Definitive proxy
19 May 22
DEFA14A
Additional proxy soliciting materials
28 Mar 22
DEF 14A
Definitive proxy
28 Feb 22
PRE 14A
Preliminary proxy
4 Feb 22
DEFA14A
Additional proxy soliciting materials
6 Dec 21
Other
EFFECT
Notice of effectiveness
13 Dec 22
CORRESP
Correspondence with SEC
8 Dec 22
UPLOAD
Letter from SEC
5 Dec 22
EFFECT
Notice of effectiveness
21 Oct 21
CORRESP
Correspondence with SEC
20 Oct 21
CORRESP
Correspondence with SEC
15 Oct 21
CORRESP
Correspondence with SEC
14 Oct 21
UPLOAD
Letter from SEC
2 Sep 21
EFFECT
Notice of effectiveness
23 Jul 19
CORRESP
Correspondence with SEC
18 Jul 19
Ownership
4
Change in insider ownership
6 Mar 24
SC 13G/A
Redmile Group, LLC
14 Feb 24
4
Change in insider ownership
12 Feb 24
SC 13D/A
Israel Biotech Fund I, L.P.
12 Feb 24
SC 13G/A
Schindel Yair Chaim
12 Feb 24
4
Change in insider ownership
21 Nov 23
SC 13D/A
Israel Biotech Fund I, L.P.
21 Nov 23
3
Yuval Cabilly
8 Nov 23
3/A
Roy Golan
3 Nov 23
3/A
Pini Orbach
3 Nov 23